European Journal of Biotechnology and Bioscience

European Journal of Biotechnology and Bioscience


European Journal of Biotechnology and Bioscience
European Journal of Biotechnology and Bioscience
Vol. 6, Issue 2 (2018)

Antimicrobial activity of Narciclasine against Escherichia coli and Candida albicans


S Kingsley Manoj Kumar, Benet Bosco Dhas, B Vishnu Bhat, Parija SC, Bhawana Badhe A

Microbial infections are a major cause of several health complications. This is partly due to the fact that available anti-microbials have become ineffective against these pathogens. Despite the advancement of science and technology, plant derived natural products are still a major source of therapeutic agents. Plants belonging to the Amarylldiaceae family have shown to have several biologically significant compounds. Narciclasine is found to be one of the useful bioactive compounds of this family as it predominantly consists of pharmacologically active alkaloids. The need for newer effective therapeutic agents against microbial infections has led us to study the anti-microbial properties of narciclasine. Here we have tested various concentration of narciclasine against two major microbial pathogens – Escherichia coli and Candida albicans. We used the microdilution method and optical density measurements to decipher the potential of narciclasine to inhibit bacterial and fungal growth. The minimum inhibitory concentration of narciclasine against E coli and C albicans was found to be 22.72µg/ml and 11.36µg/ml respectively. This study results show that narciclasine has the potential to inhibit the bacterial and fungal growth.
Download  |  Pages : 31-34
How to cite this article:
S Kingsley Manoj Kumar, Benet Bosco Dhas, B Vishnu Bhat, Parija SC, Bhawana Badhe A. Antimicrobial activity of Narciclasine against Escherichia coli and Candida albicans. European Journal of Biotechnology and Bioscience, Volume 6, Issue 2, 2018, Pages 31-34
European Journal of Biotechnology and Bioscience